{{Rsnum
|rsid=4803219
|Orientation=plus
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Chromosome=19
|position=39735919
|Gene=IL28B
|Assembly=GRCh37.p10
|GenomeBuild=37.5
|dbSNPBuild=138
|Gene_s=IFNL3
}}{{PMID Auto
|PMID=19749757
|Title=Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
}}

{{PharmGKB
|RSID=rs4803219
|Name_s=
|Gene_s=IL28B
|Feature=
|Evidence=PubMed ID:19749757
|Annotation=Phenotype: This variant is associated with null virological response (NVR) in Janapese patients with hepatitis C virus infection treated with PEG-INF-alpha plus ribavirin. Study size: 304. Study population/ethnicity: Japanese. Significance metric(s): P=2.4 x 10(-29) (NVR). Type of association: GN; CO
|Drugs=interferon alfa-2a, recombinant; ribavirin
|Drug Classes=
|Diseases=Hepatitis C; Hepatitis C, Chronic
|Curation Level=Curated
|PharmGKB Accession ID=PA165260384
}}{{PMID Auto
|PMID=21254157
|Title=Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
}}{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4803219
|overall_frequency_n=7
|overall_frequency_d=74
|overall_frequency=0.0945946
|n_genomes=3
|n_genomes_annotated=0
|n_haplomes=6
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}